Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CNR1 | P21554 | 2/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918465 | 1.00 | LMNA (0.59) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL918440 | 1.00 | LMNA (0.59) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL917679 | 0.92 | LMNA (0.46) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL26306060 | 0.90 | LMNA (0.61) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL11247302 | 0.88 | APP (0.41) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL10230800 | 0.85 | LMNA (0.41) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL10230802 | 0.85 | LMNA (0.41) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL353710 | 0.85 | LMNA (0.41) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL12531527 | 0.85 | LMNA (0.59) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL13255325 | 0.84 | LMNA (0.39) | LMNACNR1ADRA1ATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295195-A1 | ANTIMICROBIAL ORGANOSILANES | Tipikos Pharmaceuticals, Inc. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20210246344-A1 | Biological buffers with wide buffering ranges | DALY THOMAS (US) | 2021-08-12 | — | — | US | disclosed |
| US-20200071582-A1 | Biological Buffers with Wide Buffering Ranges | TPAT IP LLC | 2020-03-05 | — | — | US | disclosed |
| US-8334402-B2 | Biological buffers with wide buffering ranges | TPAT IP LLC | 2012-12-18 | — | — | US | disclosed |
| US-20110137076-A1 | Biological Buffers with Wide Buffering Ranges | TPAT IP LLC | 2011-06-09 | — | — | US | disclosed |
| US-20100190753-A1 | Methods and Compositions for Treating Amyloid-Related Diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-07-29 | — | — | US | disclosed |
| US-7598269-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2009-10-06 | — | — | US | disclosed |
| US-20080015180-A1 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-01-17 | — | — | US | disclosed |
| US-20060135403-A1 | Therapeutic formulations for the treatment of beta-amyloid related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190753-A1 | Methods and Compositions for Treating Amyloid-Related Diseases | APP, PSEN1, PSEN2 | LMNA 74/4885CNR1 3314/4885ADRA1A 981/4885 |
| US-20060135403-A1 | Therapeutic formulations for the treatment of beta-amyloid related diseases | APP, IAPP, BACE1 | LMNA 700/4885CNR1 3665/4885ADRA1A 1087/4885 |
| US-20230295195-A1 | ANTIMICROBIAL ORGANOSILANES | ARG1, ACMSD, AAAS | LMNA 4596/4885CNR1 4692/4885ADRA1A 4335/4885 |
| US-20200071582-A1 | Biological Buffers with Wide Buffering Ranges | PEF1, SLC7A1, PLPBP | LMNA 1639/4885CNR1 3404/4885ADRA1A 1544/4885 |
| US-20110137076-A1 | Biological Buffers with Wide Buffering Ranges | PEF1, SLC7A1, PLPBP | LMNA 1639/4885CNR1 3404/4885ADRA1A 1544/4885 |
| US-20080015180-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | LMNA 74/4885CNR1 3314/4885ADRA1A 981/4885 |
| US-20210246344-A1 | Biological buffers with wide buffering ranges | PEF1, SLC7A1, PLPBP | LMNA 1653/4885CNR1 3416/4885ADRA1A 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.